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Background: Gastrointestinal (GI) discomfort, e.g. bloating or rumbling, is a common symptom in otherwise
healthy adults. Approximately 20% of the population, particularly women suffer from gastrointestinal discomfort
and this affects quality of life. Recent studies discovered a link between the body and mind, called the gut-brain
axis. Psychosocial factors, such as e.g. daily stress may cause altered gut physiology leading to ileum contractions
and consequently gastrointestinal symptoms. In vitro and ex vivo studies clearly showed that a Perilla frutescens
extract combines prokinetic, antispasmodic and anti-inflammatory effects. The aim of the intervention was to investigate
the effects of the proprietary Perilla extract on GI discomfort in healthy subjects with gastrointestinal discomfort and
reduced bowel movements in comparison to a placebo product.
Methods: The pilot study was performed according to a double-blind, randomized, placebo-controlled parallel design.
Fifty healthy subjects with gastrointestinal discomfort and reduced bowel movements, 30-70 years, documented their GI
symptoms, stool frequency and consistency daily during a 2-week run-in phase and a 4-week intervention phase with
Perilla frutescens extract or placebo. GI symptoms were assessed on a 5-point scale daily and average scores over 14 days
intervals were calculated.
Results: All GI symptoms were significantly improved over time by Perilla frutescens extract during the intervention phase
(bloating: -0.44 ± 0.56, p = 0.0003; passage of gas: -0.30 ± 0.66, p = 0.0264; GI rumbling: -0.55 ± 0.87, p = 0.0014; feeling of
fullness: -0.36 ± 0.72, p = 0.0152; abdominal discomfort: -0.54 ± 0.75, p = 0.004), whereas in the placebo group
only abdominal discomfort was significantly improved (-0.31 ± 0.55, p = 0.0345). In the subgroup of women
results were strengthened and a subscore out of bloating and abdominal discomfort was significantly improved
against placebo (95%CI 0.003 to 0.77; p = 0.048).
Conclusion: The demonstrated effects of Perilla frutescens extract to improve GI complaints offer very promising
results, taking into consideration the challenging set up of a nutritional human study with healthy subjects and
in the area of digestive health, which is known for high placebo effects.
Trial registration number: NCT01931930 at ClinicalTrials.gov, Registration date 23rd August 2013.
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Gastrointestinal (GI) discomfort often accompanied by
bloating or rumbling, is a common symptom in otherwise
healthy adults. Approximately 20% of the population, par-
ticularly women, suffers from GI discomfort and these dis-
orders affect quality of life [1-3]. Often, a reduced ability
to work and participate in social or recreational activities
is reported. Consumer research indicates that today one
third of consumers looking for gut health support do not
find an effective product that alleviates any of their dis-
comfort [4]. This may be related to the fact that even
people with a healthy gut microflora and no food intoler-
ance suffer from digestive discomfort. Recent studies show
a link between the body and mind, called the gut-brain
axis. Psychosocial factors, such as daily stress may cause
altered gut physiology leading to ileum contractions and
consequently GI symptoms [5]. In this context, Perilla fru-
tescens might be an interesting plant. The proprietary Pe-
rilla frutescens leaf extract contains a specific ratio of
selected flavonoids, particularly vicenin-2 (apigenin-6,8-di-
C-glycoside) in combination with rosmarinic acid; all ac-
tive compounds naturally found in Perilla. Perilla frutes-
cens (L.) Britton is an annual edible herbaceous plant
native to Asia. Common names are Shiso, Japanese melis-
sea or Japanese basil. Perilla belongs to the mint family,
Lamiaceae. The green Perilla leaves are used as tea, food
or spice [6]. In vitro and ex vivo studies clearly showed
that the proprietary Perilla frutescens extract combines
prokinetic and antispasmodic as well as anti-inflammatory
effects [7,8]. The study was designed with the aim to de-
velop a health claim substantiated food ingredient and
thus comply with EFSA (European Food Safety authority)
requirements [9]. It is challenging to show beneficial gut
health effects within a target population of healthy people.
However, the intention is to demonstrate an improvement
of a physiological status which is defined as healthy yet af-
fects quality of life. In addition it is known that human
studies investigating GI health show a high placebo effect
[10,11]. Digestive health related questionnaires, validated
on healthy people are not available to investigate the influ-
ence on symptoms and quality of life. EFSA recommends
using a validated questionnaire and therefore, it was neces-
sary to evaluate if the questionnaires which were validated
on patients presenting with GI disorders (i.e. a diseased
population group) would be suitable for application in a
study with healthy volunteers with GI discomfort.
Methods
Study design
The pilot study was a mono-center, randomized, double-
blind, placebo-controlled, human pilot study with paral-
lel design. Prior to trial start, volunteers were screened
for their eligibility to take part in the nutritional inter-
vention trial. Eligible subjects were then entered into a2-week run-in phase to provide baseline measurements
of stool frequency and consistency as well as GI discom-
fort. During the run-in phase subjects did not consume
any study products. At the start of the consumption
phase (visit 1) the subjects were randomly assigned to
one of the two study groups (ratio 1:1). During the 4-
week intervention phase the subjects consumed the
study product (Perilla frutescens extract) or the placebo
product (Tapioca starch) according to the randomization
scheme. The study was a nutritional study and con-
ducted in accordance with ICH-GCP guideline and in
compliance with the declaration of Helsinki. The study
was reviewed and approved by the Institutional Review
Board (IRB) “Landesärztekammer Baden-Württemberg”
and all subjects signed the IRB-approved Informed Con-
sent prior to any procedures being conducted.
Subject population
Fifty healthy male and female volunteers between 30 and
70 years of age with reduced bowel movements and
gastrointestinal discomfort were enrolled via public notice
board and advertisement in newspapers. Forty-seven (9
male and 38 female) volunteers finished the study in ac-
cordance to the protocol (Figure 1). The study was per-
formed from July to November 2012 at BioTeSys GmbH,
Esslingen, Germany an independent study site which fo-
cused on nutritional research. Before study entrance the
volunteers were medically checked for their physical con-
dition and they had to fulfill all inclusion criteria and none
of the exclusion criteria (Table 1).
Intervention
The active product tested is a proprietary Perilla frutescens
extract obtained by water extraction out of dried Perilla
frutescens leaves, an annual edible herbaceous plant, native
to Asia. Perilla frutescens is a member of the family Lamia-
ceae. Perilla fructescens extract is a food supplement. The
extract is hydrophilic and can easily be dissolved in water.
It comprises e.g. 10 different flavonoids, caffeic acid and
rosmarinic acid and was characterized by a chromato-
graphic fingerprint in Figure 2 obtained by using the follow-
ing reverse phase high performance liquid chromatography
(RP-HPLC) method. RP-HPLC was performed using a
Hitachi apparatus equipped with a L-7420 detector (at
320 nm) and a 250 × 4.6 mm I.D., 5 μm, ODS, Capsule
Pack UG-120 (Shiseido, Japan). Separation was achieved
with an increasing number of 0.1 percent acetic acid, 5 per-
cent methanol and 10 percent water in acetonitrile (B) in
0.1 percent aqueous acetic acid (A): 0–10 min, 12.5 percent
B, isocratic; 10–25 min, 12.5–90 percent B, linear gradient;
25–30 min, 90 percent B, isocratic; 30–31 min, 90–12.5
percent B, linear gradient; and 31–40 min, 12.5 percent B,
isocratic at a flow rate of 0.8 ml/min. The method was vali-
dated according to ICH-guidelines, using double evaluation
Figure 1 Study flow.
Table 1 In- and exclusion criteria for the participation at the study
Inclusion criteria Exclusion criteria
○ Healthy volunteers without clinical diagnosed diseases with
relevant effect on the gastrointestinal system or on visceral motility
○ Subject under prescription for medication for digestive symptoms such as
anti-spasmodic, laxatives and anti-diarrheic drugs or other digestive auxiliaries
○ Reduced bowel movements defined as an average of >1
and≤ 3.5 stools per week for at least the previous 6 months
○ Relevant history, presence of any medical disorder or intake of medication/
dietary supplements, potentially interfering with this trial at screening
○ BMI: 19-30 kg/m2 ○ Subjects with stool frequency of ≤ 1 stool every 7 days
or > 3.5 stools per week
○ Gastrointestinal symptoms of at least 5 points ○ Subjects not willing to avoid pre- and probiotics for the duration of the study
○ Male or female ○ Intake of antibiotics in the last 4 weeks and laxatives in the last 2 weeks
○ Age≥ 30 and≤ 70 years ○ Change of dietary habits within the 4 weeks prior to screening
(for instance start of a diet high in fibers)
○ Nonsmoker ○ Pregnant subject or subject planning to become pregnant during
the study; breast-feeding subject
○ Written consent to participate in the study ○ Subjects with history of drug, alcohol or other substances abuse,
or other factors limiting their ability to co-operate during the study
○ Able and willing to follow the study protocol procedures ○ Participants anticipating a change in their lifestyle or physical activity
levels since this may also influence the results
○ Known food intolerance or allergy
○ Subject involved in any clinical or food study within the preceding month
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Figure 2 Perilla frutescens leaf special extract – HPLC chromatogram. 1: Caffeic Acid; 2: Vicenin 2 (Apigenin 6,8-di-C-diglucoside); 3: Luteolin
7-O-[β-glucuronosyl(1➔2) β-glucuronide];4: Apigenin 7-O-[β-glucuronosyl(1➔2) β-glucuronide]; 5: Luteolin 7-O- β-glucuronide; 6: Scutellarein
7-O- β-glucuronide; 7: Rosmaric Acid; 8: Apigenin 7-O- β-glucuronide; 9: Luteolin; 10: Apigenin.
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The proprietary Perilla frutescens extract, also known as
Benegut®, was supplied by Vital Solutions GmbH, Germany
(Dr. Sybille Buchwald-Werner) and the Company Amino
Up Chemical Co, Ltd. (Dr. Hajime Fujii), Sapporo, Japan.
The placebo was provided by the manufacturer and
matched in size and color to the active product. All sub-
jects were instructed to take 2 capsules daily, one in the
morning and one in the evening before food intake with
sufficient water for the 4 weeks duration of the interven-
tion phase.
Each capsule contained 150 mg Perilla frutescens ex-
tract or placebo.
Assessment
After check for eligibility during screening, subjects were
randomly assigned to the study groups after allocating
subject numbers in chronologic order by study staff. To
ensure double-blind performance the randomization
scheme was created by Vital Solutions using the soft-
ware Randlist with blocksize of 4. Subjects were strati-
fied for gender and age (30-49 years and 50-70 years).
All subjects, the investigator and the whole study staff
involved in study performance and data analysis were
blinded until database lock and deblinding.
After randomization, all subjects documented their GI
symptoms, stool frequency and consistency daily during
the 2-week run-in phase and the 4-week intervention
phase. Additionally questionnaires were filled in at the be-
ginning (visit 1) and at the end of the intervention phase
(visit 2). For assessment of GI symptoms, the subjects
were asked to grade daily in the evening the average inten-
sity over the previous 24 hours on a 5-point scale from 0
(not at all) to 4 (extremely) for the following GI character-
istics: bloating/distension, passage of gas, GI rumbling,
feeling of fullness and abdominal discomfort. All answers
were evaluated separately and a total score summarizing
all assessed GI symptoms as well as a score for bloating
and abdominal discomfort was calculated. For evaluationaverage scores over 14 days intervals were calculated.
Additionally, the stool frequency was documented and
consistency rated using the Bristol Stool Form Scale [12].
The Patient Assessment of Constipation Symptoms
(PAC-SYM) questionnaire, a 12-item self-reporting instru-
ment divided into abdominal, rectal and stool domains,
was used to assess the constipation symptoms at the be-
ginning and end of supplementation retrospectively. A
scale with 5 categories is used to assess the different symp-
toms [13]. Additionally, the questionnaire “Patient Assess-
ment of Constipation Quality of Life (PAC-QOL)”, that
provides information about the special distraction of daily
life and general well-being of volunteers because of consti-
pation, was also assessed [14]. Within the nutritional trial
the two sub-scores focused to physical discomfort and sat-
isfaction were recorded. Both questionnaires are develop
and validated in a patient population with a history of
chronic constipation. The perceived stress questionnaire
(PSQ20) [15] is a tool that assesses subjectively experienced
stress independent of a specific or objective occasion. It
was evaluated before and after the intervention phase and
consists of 4 domains, worries, tension, joy and demands
with 5 items each. The questionnaire was assessed to in-
clude and confirm that the overall stress-levels remained
unchanged during the study. Furthermore, subjects were
instructed at the beginning of the study not to change their
nutrition or sports habits during the study. This was con-
trolled at the end of the study by interview.
Statistics
Statistics was performed using GraphPad Prism 5.0. The
study was conducted as pilot study to get a first overview
about efficacy of Perilla extract in the field of gastrointes-
tinal discomfort in humans. Therefore, all efficacy end-
points were evaluated exploratory. As no literature for this
specific question was available for the a priori sample size
calculation the sample size for the current study was
chosen in orientation to other literature in the field of
bowel function and gut health [16-20]. Finally, a sample
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view and basis for further research. Within the analysis, all
volunteers with visits under supplementation were statisti-
cally evaluated (n = 47). All statistical tests were performed
two-sided. A probability level of 0.05 or less was consid-
ered to indicate statistical significance. No adjustment to
multiple endpoints was performed due to the exploratory
character. GI-symptoms were evaluated over 2-week inter-
vals averaging daily scoring data. To show changes over
time, a mean score for the run-in period, the first two
weeks of intervention and the last two weeks of interven-
tion was calculated. Delta changes of GI symptoms were
calculated for the last 2 weeks of intervention phase and
baseline levels during run-in phase. Subjects showing im-
provement of GI symptoms were defined as responders if
delta change between the last two weeks of intervention
and baseline was <0. Based on this definition, responder
rates were calculated for the GI symptoms. As the require-
ments for a chi square test were not fulfilled due to n < 5
in the group of non-responders in the Perilla group, the
results of responder rates were only reported descriptively.
Stool consistency was documented each day with bowel
movement and evaluated as mean levels in 2-week inter-
vals. Perceived Stress Questionnaire (PSQ20) was assessed
before and after supplementation phase. For these previ-
ously described parameters, parametric approaches were
used, as these data were normally distributed. Paired t-test
or Repeated measures analysis of variance (ANOVA) was
performed to check for changes over time within group
and unpaired t-test was performed for delta changes of Pe-
rilla and placebo group to check for differences between
groups. Stool frequency, PAC-SYM and PAC-QOL were
evaluated with non-parametric tests. Stool frequency
(number of days with bowel movement) was evaluated
over 2-week intervals and treatment effects were investi-
gated for the delta changes of stool frequency between
run-in phase and last 2 weeks of intervention phase. PAC-
SYM and PAC-QOL were assessed before and after sup-
plementation phase. Changes within and between groups
were checked with Wilcoxon Matched Pairs Signed Rank
Test or Mann Whitney Test, as appropriate.
Figures are depicted as scatter plots, indicating mean
and 95% confidence interval.
In general, females tend to suffer more from GI discom-
fort and reduced bowel movements [1,3,21]. Therefore,
parameters were additionally evaluated in the subgroup of
women.
Results
Subjects included in the study were in mean 51 years
old, with a BMI of 24 kg/m2. As shown in Table 2, the
study was conducted within a general population with a
tendency to reduced bowel movements per week and
due to the fact, that women are suffering more fromgastrointestinal discomfort [1,3,21], more women than
men were included. Characteristics of intervention
groups were comparable at baseline (Table 3 run-in).
The daily investigated GI discomfort symptoms de-
clined by the intake of Perilla extract. Bloating, passage of
gas, GI rumbling, feeling of fullness and abdominal discom-
fort improved significantly over time (repeated measures
ANOVA) from the run-in phase until the end of supple-
mentation phase in the Perilla group (bloating: -0.44 ± 0.56,
p = 0.0003; passage of gas: -0.30 ± 0.66, p = 0.0264; GI rum-
bling: -0.55 ± 0.87, p = 0.0014; feeling of fullness: -0.36 ±
0.72, p = 0.0152; abdominal discomfort: -0.54 ± 0.75, p =
0.004), whereas in the placebo group only abdominal dis-
comfort was significantly improved (-0.31 ± 0.55, p =
0.0345) (Table 3). Figures 3 and 4 are showing the course of
effect on bloating and abdominal discomfort over time, ex-
emplarily. The placebo effects were only measurable after
4 weeks of intake, whereas the Perilla extract effects were
measurable already in the first part of intervention and
were even strengthened with ongoing supplementation.
Additional descriptive calculation of responder rates indi-
cated in Perilla group higher responder rates in comparison
to placebo (Perilla: bloating 83%, passage of gas 67%, GI
rumbling 71%, feeling of fullness 67%, abdominal discom-
fort 71% // Placebo: bloating 57%, passage of gas 52%, GI
rumbling 57%, feeling of fullness 52%, abdominal discom-
fort 48%). This was especially pronounced for “bloating”
with 83% responder in Perilla versus 57% in placebo group.
In the subgroup of women, the reduction of GI symp-
toms by supplementation of Perilla extract appeared even
more pronounced. All five GI symptoms decreased signifi-
cantly over time within the perilla group (repeated mea-
sures ANOVA) (bloating: -0.51 ± 0.57, p = 0.0002; passage
of gas: -0.34 ± 0.60, p = 0.0272; GI rumbling: -0.74 ± 0.85,
p = 0.0002; feeling of fullness: -0.45 ± 0.73, p = 0.0062; ab-
dominal discomfort: -0.63 ± 0.79, p = 0.0004), whereas in
the placebo group none of the symptoms decreased sig-
nificantly over time (see also Table 4).The benefit of perilla
in comparison to placebo in the subgroup of women was
seen by trend for the following GI symptoms: bloating
(95%CI -0.031 to 0.79, p = 0.069) (Figure 3), GI rumbling
(95%CI -0.080 to 0.95, p = 0.095) and abdominal discom-
fort (95%CI -0.0314 to 0.83, p = 0.068) (Figure 4). In
women, the summary score out of all 5 GI symptoms
showed significant reduction in the Perilla group (-0.54 ±
0.61, p = 0.0001). The symptoms decreased from 1.37 ±
0.71 at run-in, over 1.11 ± 0.54 after 2 weeks of intake to
0.83 ± 0.56 after 4 weeks of intake. This reduction of GI
symptoms in the Perilla group showed a difference by
trend in comparison to placebo (95%CI -0.02 to 0.73, p =
0.062) (Figure 5). The comparison of the sub-score includ-
ing bloating and abdominal discomfort showed statistically
significant results between Perilla and placebo in the fe-
male group (95%CI 0.003 to 0.77, p = 0.048) (Figure 5).
Table 2 Demographic data and baseline characteristics for the whole sample size and the subgroup women
Group (N) Age [a] BMI [kg/m2] Chol [mg/dl] Systolic [mmHg] Diastolic [mmHg] Days with stool/ week
Whole sample size Placebo (23) 51 ± 8 24.4 ± 3.5 218 ± 45 120 ± 16 77 ± 9 2.83 ± 0.47
Perilla (24) 51 ± 12 24.4 ± 3.2 231 ± 46 124 ± 14 77 ± 9 2.75 ± 0.47
Subgroup women Placebo (19) 50 ± 9 24.2 ± 3.7 222 ± 46 118 ± 17 75 ± 9 2.84 ± 0.50
Perilla (19) 53 ± 11 24.0 ± 3.4 244 ± 42 123 ± 15 77 ± 9 2.76 ± 0.39
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showed higher responder rates for the Perilla extract
group in comparison to placebo. (Perilla: bloating 84%,
passage of gas 74%, GI rumbling 79%, feeling of fullness
68%, abdominal discomfort 74% // Placebo: bloating 47%,
passage of gas 47%, GI rumbling 58%, feeling of fullness
47%, abdominal discomfort 47%).
These effects were most pronounced for “bloating”
with 84% responders in Perilla versus 47% in Placebo
group.
The delta changes of stool frequency between the run-in
and the intervention phase did not show significant differ-
ences between groups. In the placebo group number of
days with stool per week increased about 0.8 ± 1.02 and
slightly higher about 0.83 ± 1.4 in the Perilla group. Stool
consistency assessed with Bristol Stool Form Scale tended
to become softer in both groups. The placebo group im-
proved from 2.42 ± 0.86 to 3.2 ± 1.1 and Perilla from 2.47 ±
1.01 to 2.9 ± 1.1. The total score of PAC-SYM was signifi-
cantly improved in both groups (Placebo: 95%CI 0.246 to
0.699, p = 0.0002; Perilla: 95%CI 0.152 to 0.520, p = 0.0257).
However, in comparison between groups there were no sig-
nificant differences. Overall reported symptoms and
changes in symptoms were very low and in most cases only
around the category 1 (mild). The results of the PAC-QOLTable 3 Mean values and standard deviation (SD) for the who
changes between the run in phase and the intake phase (wee
Whole sample










Run In Intake we
1-2
Bloating 1.45 1.44 1.2 0.0733 1.42 1.28
SD 0.74 0.72 0.77 0.81 0.64
Passage of gas 1.47 1.57 1.37 0.2284 1.6 1.5
SD 0.66 0.53 0.62 0.77 0.62
GI rumbling 1.51 1.33 1.18 0.0635 1.64 1.27
SD 0.86 0.91 0.83 0.85 0.6
Feeling of fullness 1.08 1.05 0.83 0.0987 1.03 0.84
SD 0.8 0.59 0.62 0.77 0.63
Abdominal
discomfort
1.15 1.06 0.84 0.0345 1.25 0.92
SD 0.93 0.84 0.81 0.86 0.61
For the comparison within group p values of repeated measures ANOVA and for th
are shown.showed also no significant changes between groups. The
results of the Perceived Stress Questionnaire (PSQ20)
showed no differences within and between groups during
intervention.
Most of subjects followed the order not to change
their nutrition or sports habits during the study. Only
two subjects reported about somewhat more and one
subject about somewhat less physical activity. Neverthe-
less these deviations were only minor and no interfer-
ence with study results is expected.
At each visit, adverse events and concomitant medica-
tion were documented. Most adverse events were head-
ache and common colds, which were not related to the
study product. One subject was down with gastroenter-
itis. A relationship to the study product is improbable.
Discussion
The results of the human study show that Perilla extract is
able to improve gastrointestinal discomfort symptoms. Pe-
rilla extract improved all GI discomfort symptoms (bloat-
ing, passage of gas, GI rumbling, feeling of fullness and
abdominal discomfort) significantly over the 4-week inter-
vention. Placebo was only able to reduce abdominal dis-
comfort significantly after 4 weeks of intake. The placebo
















0.98 0.0003 -0.25 -0.44 -0.194 to 0.562
0.78 0.71 0.56
1.3 0.0264 -0.10 -0.30 -0.177 to 0.577
0.74 0.62 0.66
1.09 0.0014 -0.33 -0.55 -0.251 to 0.685
0.81 0.71 0.87
0.67 0.0152 -0.24 -0.36 -0.288 to 0.515
0.63 0.64 0.72
0.71 0.0004 -0.31 -0.54 -0.156 to 0.621
0.74 0.55 0.75
e comparison between groups the 95% confidence intervals of differences
Figure 3 Distribution of bloating. Bloating during the run-in
period (V1), the first two weeks (V2_1) and the last two weeks (V2_2)
of intake phase (Placebo p = 0.0733, Perilla p = 0.0003; Repeated
measures ANOVA).
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in the first part of intervention and were even strength-
ened with ongoing supplementation. Perilla extract
showed consistently higher reduction in gastrointestinal
symptoms compared to placebo. In female subjects, these
differences were even more pronounced than in the whole
study group, and bloating, GI rumbling as well as abdom-
inal discomfort were improved by trend in the PerillaFigure 4 Distribution of abdominal discomfort. Abdominal
discomfort during the run-in (V1), period, the first two weeks (V2_1)
and the last two weeks (V2_2) of intake phase. (Placebo p = 0.0345,
Perilla p = 0.0004; Repeated measures ANOVA).extract group if compared to placebo. Furthermore, the
sub-score including bloating and abdominal discomfort
showed significant results for the female group (p = 0.048).
Especially in females, but also in the whole study popula-
tion, the Perilla extract group showed consistently higher
responder rates to gastrointestinal symptom relief. Re-
sponder rates demonstrated physiological relevance of Pe-
rilla extract for reduction of GI symptoms. The results of
the trial confirm that Perilla extract is able to improve the
postulated main targeted GI discomfort parameter, refer-
ring to its mode of action, as Perilla extract has proven pro-
kinetic and anti-spasmodic efficacy, beneficial to reduce
these symptoms [7,21]. In the study the effects of Perilla ex-
tract in comparison to Tapioca starch, a fully digestible
carbohydrate (placebo control), on gastrointestinal discom-
fort and bowel function were investigated. The study was
conducted according to a double-blind and placebo-
controlled design with a 4-week intervention period.
Gastrointestinal discomfort often accompanied by bloating
or rumbling, is a common symptom in otherwise healthy
adults. The aim of the study was the evaluation of Perilla
extract on a representative group of the general population.
Therefore a population with reduced bowel movement and
gastrointestinal discomfort, but otherwise healthy was in-
cluded. Approximately 20% of the population, particularly
women, suffers from GI discomfort and these disorders
affect quality of life [1,2]. To meet the higher number of af-
fected women in the general population, more women than
men were included. The challenge of the study was, to
demonstrate improvements of GI symptoms in the general
population with only little occurrence, especially as avail-
able evaluation tools in most cases are developed for a
diseased population [13,14]. Therefore one reason for per-
forming a pilot trial with Perilla extract, besides the con-
tainment of the area of gut health where Perilla extract
shows its potential, was to find suitable tools for the
healthy population with only little occurrence of symp-
toms. The daily documentation of GI symptoms including
bloating, passage of gas, GI rumbling, feeling of fullness
and GI discomfort, was a direct measure of occurrence of
a set of predominant gastrointestinal symptoms which
was very well accepted by participants. Nevertheless, the
sensitivity of the questions could be increased in further
studies by increasing the rating scale, to possibly meet the
little occurrence of symptoms. The problematic of a lack
of recognized markers for measuring gastrointestinal well-
being and digestive symptoms in the general population
was also assessed by Guyinnet et al. [22]. Possibly, this
newly developed tool as a measure of GI well-being im-
provement can also be added in further studies. As symp-
toms of gastrointestinal discomfort and the constipation
of stool are more or less intravariable acts, it is important
to have a run-in period, long enough, to have meaningful
baseline values. In the current study, baseline conditions
Table 4 Mean values and standard deviation (SD) for women of Gastrointestinal symptoms and the delta changes
between the run in phase and the intake phase (week 3-4)
Women
(N = 38)
















3-4 to run in
Delta week




Bloating 1.54 1.65 1.4 0.1641 1.43 1.27 0.91 0.0002 -0.14 -0.51 -0.031 to 0.787
SD 0.67 0.58 0.68 0.85 0.71 0.83 0.67 0.57
Passage of gas 1.54 1.69 1.49 0.2572 1.62 1.51 1.28 0.0272 -0.04 -0.34 -0.126 to 0.727
SD 0.65 0.47 0.59 0.81 0.68 0.77 0.60 0.69
GI rumbling 1.6 1.47 1.3 0.1685 1.64 .1.17 0.9 0.0002 -0.30 -0.74 -0.080 to 0.948
SD 0.78 0.92 0.85 0.81 0.59 0.68 0.70 0.85
Feeling
of fullness
1.05 1.13 0.86 0.1016 0.96 0.76 0.51 0.0062 -0.19 -0.45 -0.173 to 0.709
SD 0.78 0.61 0.67 0.79 0.67 0.59 0.60 0.73
Abdominal
discomfort
1.14 1.16 0.91 0.0843 1.2 0.83 0.57 0.0004 -0.24 -0.63 -0.031 to 0.828
SD 0.87 0.84 0.84 0.89 0.64 0.65 0.48 0.79
For the comparison within group p values of repeated measures ANOVA and for the comparison between groups the 95% confidence intervals of differences
are shown.
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http://www.biomedcentral.com/1472-6882/14/173for GI discomfort and bowel function parameters assessed
during the run-in phase were comparable between groups
and volunteers suffered at least 6 months from reduced
bowel movements. The data of the perceived stress ques-
tionnaire confirmed, that there was no change of overall
stress level during the study. Also no relevant changes of nu-
trition or activity status during the study were documented.
However, there were some limitations of the study.
Until the beginning of the study, there was no experi-
ence from literature, in which area of gastrointestinal
discomfort Perilla extract shows primary effectiveness.
However, due to ex vivo and in vitro results a balancing
effect was anticipated. Therefore a lot of parameters
concerning gastrointestinal discomfort were assessed
during the study and no primary objective was defined,
thus the character of a pilot study was chosen. Due to
lack of literature with Perilla extract in the field of gutFigure 5 Mean differences of GI symptoms. GI symptoms between the
(Δ1: p = 0.0691; Δ2: p = 0.0951, Δ3: p = 0.0676; *4: p = 0.048 Δ5:: p = 0.0621 , unhealth or GI symptoms, no a priori sample size calculation
was performed and determination of sample size was only
estimated according to literature with similar questions.
The results show very promising results, and it seems as
Perilla extract is able to improve gastrointestinal symptoms
in the observed population. Nevertheless, the results could
not demonstrate significant advantage of Perilla extract
over placebo for each parameter even if there are clear
hints. An underestimated sample size or less sensitivity of
used questionnaires has to be considered as possible rea-
sons for lacking significance. Results are also offering indi-
cation for future studies, which tools are suitable and which
are potential primary objectives for evaluation of Perilla ex-
tract’s effects in the area of digestive health. On this basis,
further research with higher sample size and possibly
adapted questionnaires will confirm the effectiveness of Pe-
rilla extract to reduce gastrointestinal discomfort.last two weeks of supplementation and the run-in phase for women.
paired t-test).
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http://www.biomedcentral.com/1472-6882/14/173Another challenge of research in the field of GI discom-
fort is the known placebo effect for human studies investi-
gating gastrointestinal health [10,11]. Literature reports
indicate that placebo effects in studies on gastrointestinal
function range from 10% to 70% for functional dyspepsia
[23] and 0% to 84% for irritable bowel syndrome [11]. In
the current study also a high placebo effect could be ob-
served in each parameter (around 60%), which compli-
cates the recognition of clear effects. Nevertheless the
results of the study show an advantage for Perilla extract
over placebo. Consumer research indicates that today one
third of consumers looking for gut health support do not
find an effective product that alleviates any of their dis-
comfort. In addition also patients with irritable bowel syn-
drom or irritable bowel disease wish to apply or as a
matter of fact use food supplements or complementary
and alternative medicines [24,25]. Many indications for
the use of such remedies are anecdotally or traditionally
derived. Physicians are looking for alternative therapies,
co- medications or food supplements which demonstrated
beneficial effects within randomized controlled trials. The
promising results shown for Perilla extract, a food grade
ingredient, could benefit consumer with GI discomfort
and patients suffering from GI diseases.
Conclusion
The demonstrated effects of Perilla extract to improve
GI discomfort offer very promising results taking into
consideration the challenging set up of a nutritional hu-
man study with healthy volunteers and in the area of di-
gestive health, which is known for high placebo effects.
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